Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review

TL;DR

This study suggests that perioperative use of NSAIDs during breast cancer surgery significantly reduces early relapse rates, potentially by blocking inflammation-driven mechanisms that activate dormant cancer cells.

Contribution

It provides new evidence that perioperative NSAID administration can markedly decrease early breast cancer relapses, highlighting a simple intervention to improve patient outcomes.

Findings

NSAID use reduced early relapse hazard by 5-fold

Perioperative anti-inflammatory treatment improved 5-year disease-free survival

Surgical inflammation may trigger early cancer relapses

Abstract

To explain a bimodal pattern of hazard of relapse among early stage breast cancer patients identified in multiple databases, we proposed that late relapses result from steady stochastic progressions from single dormant malignant cells to avascular micrometastases and then on to growing deposits. However in order to explain early relapses, we had to postulate that something happens at about the time of surgery to provoke sudden exits from dormant phases to active growth and then to detection. Most relapses in breast cancer are in the early category. Recent data from Forget et al suggests an unexpected mechanism. They retrospectively studied results from 327 consecutive breast cancer patients comparing various perioperative analgesics and anesthetics in one Belgian hospital and one surgeon. Patients were treated with mastectomy and conventional adjuvant therapy. Relapse hazard updated Sept 2011 are presented. A common Non-Steroidal Anti-Inflammatory Drug (NSAID) analgesic used in surgery produced far superior disease-free survival in the first 5 years after surgery. The expected prominent early relapse events in months 9-18 are reduced 5-fold. If this observation holds up to further scrutiny, it could mean that the simple use of this safe, inexpensive and effective anti-inflammatory agent at surgery might eliminate early relapses. Transient systemic inflammation accompanying surgery could facilitate angiogenesis of dormant micrometastases, proliferation of dormant single cells, and seeding of circulating cancer stem cells (perhaps in part released from bone marrow) resulting in early relapse and could have been effectively blocked by the perioperative anti-inflammatory agent.